Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2 and removed older notices (including the lapse in government funding notice and Revision: v3.4.1), which are cosmetic updates and do not modify the study details or core content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check21 days agoChange DetectedThe page now includes a government funding lapse notice with a status update for the NIH Clinical Center, and the site version was updated to v3.4.1, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedThe page adds a Show glossary option and updates metadata labels (Last Update Submitted that Met QC Criteria; Revision: v3.4.0), replacing the previous labels (Last Update Submitted that met QC Criteria) and the No FEAR Act data note.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision history updated: added Revision v3.3.4 and removed Revision v3.3.3.SummaryDifference0.1%

- Check63 days agoChange DetectedA new footer revision notice 'Revision: v3.3.3' appears, and the previous 'Revision: v3.3.2' text as well as the 'HHS Vulnerability Disclosure' link have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check91 days agoChange DetectedRevision: v3.3.2 was added and v3.2.0 was removed on the page. This is a maintenance update that does not affect study details or how users interact with the page.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.